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ABSTRACT
Agents that increase intracellular cyclic 3’,5’-adeno-
sine monophosphate (cAMP), such as forskolin,
prostaglandin (PG)E2, salbutamol and 8-bromo-cAMP,
have been shownto inhibit the proliferation of airway
smooth-muscle (ASM) cells in vitro. However, it has not
yet been determined whether selective inhibitors of
phosphodiesterase (PDE) isoenzymes III and IV that
catalyze cAMPto 5’-adenosine monophosphate have
the ability to inhibit ASM cell proliferation. To evaluate
the effectsof PDE inhibitors on ASM cell proliferation,
ASM cells isolated from bovine tracheae were cultured
in the presence of fetal bovine serum (FBS), with or
without a non-selective PDE inhibitor (theophylline), a
selective PDE III inhibitor (cilostazol), and a selective
PDE IV inhibitor (rolipram). The number of ASM cells
cultured with 5% FBS was significantly reduced by the
presence of theophylline at 10–3 and 3 · 10–4 mol/L,
cilostazol at 10–5, 10–6 and 10–7 mol/L, and rolipram
at 10–4 and 10–5 mol/L. The release of lactic dehydro-
genase from ASM cells cultured with any concentration
of these agents was not significantly different from that
with medium alone. Inhibitors of PDE III and IV were
demonstrated to have an inhibitory effect on ASM cell
proliferation induced by FBS. Our results suggest the
value of the further development of PDE inhibitors for
the treatment of hyperplasia of ASM cells characteristic
of airway remodeling, in addition to bronchospasm
and airway inflammation, in bronchial asthma.
Key words: phosphodiesterase inhibitors, proliferation,
tracheal smooth muscle cells.
INTRODUCTION
One of the histologic features in the airways of patients
with bronchial asthma is hypertrophy/hyperplasia of air-
way smooth muscle (ASM) cells.1 The structural change 
of ASM, together with subepithelial fibrosis and hyper-
trophy/hyperplasia of submucosal glands, leads to
thickening of the airway walls, resulting in the aggrava-
tion of the chronicity and severity of bronchial asthma by
amplifying airway narrowing.2 Several factors present in
the airways of asthmatics, which include platelet-derived
growth factor, transforming growth factor-b 1, tumor necro-
sis factor-a , substance P, histamine, leukotriene D4 and
tryptase, have been reported to promote the proliferation
of ASM cells in vitro.3–6 The activation of phospholipase C,
tyrosine kinase and mitogen-activated protein kinase has
been reported to be involved in the growth responses of
ASM cells.7,8 On the other hand, salbutamol, prosta-
glandin E2, forskolin, vasoactive intestinal peptide (VIP)
and 8-bromo-cyclic 3’,5’-adenosine monophosphate 
(8-bromo-cAMP) have been demonstrated to inhibit the
proliferation of ASM cells via a rise of intracellular cyclic
3’,5’-adenosine monophosphate.9,10
Cyclic 3’,5’-adenosine monophosphate and cyclic
3’,5’-guanosine monophosphate (cGMP) are well
known as second messengers mediating intracellular
signal transduction evoked by the binding of agonists to
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their cell surface receptors. The concentration of intra-
cellular cAMP/cGMP is dependent on the catalysis rate
of adenosine/guanosine 5’-triphosphate to cAMP/cGMP
by adenylate/guanylate cyclase and cAMP/cGMP to
5’-adenosine/guanosine monophosphate by phosphodi-
esterase (PDE). The PDE comprise at least seven families of
isoenzymes (types I–VII), the differentiation of which is
based on the primary protein and cDNA sequence, sub-
strate specificity, regulation of enzymatic activity and
calcium/calmodulin dependence. Of the seven PDE iso-
enzymes, types III and IV hydrolyze cAMP, and type V
cGMP.11 Biochemical analysis has identified five distinct
PDE isoenzymes (I, II, III, IV and V) in human and bovine
tracheal smooth muscle. Phosphodiesterases III, IV and V
are abundant in bronchus and trachea, while PDE I and II
are sparse. Pharmacological investigations using selective
and non-selective inhibitors of PDE isoenzymes have
shown that PDE type III and IV inhibitors are more effective
than PDE type I, II and V inhibitors in bronchorelaxation.12
With regard to the effects of PDE inhibitors on the growth of
ASM cells, a non-selective PDE inhibitor (3-isobutyl-1-
methylxanthine; IBMX) has been shown to inhibit the
proliferation of human ASM cells via a rise of cAMP.9
However, the effects of selective PDE inhibitors have not yet
been determined, although selective inhibitors of PDE III
and IV, as well as IBMX, have been demonstrated to inhibit
mitogenesis of vascular smooth muscle cells.13
Therefore, in this study we investigated the effects on
fetal bovine serum-induced bovine ASM cell proliferation
of selective inhibitors of PDE III (cilostazol) and PDE IV
(rolipram), as well as a non-selective PDE inhibitor (theo-
phylline), which has been widely used for the treatment of
bronchial asthma. 
METHODS
Preparation of ASM cells
Airway smooth muscle cells were obtained from bovine
tracheae as described previously, with some modifica-
tions.14 Fresh bovine tracheae were obtained from a
slaughterhouse. Small strips of the tracheal muscle
were dissected from epithelium and connective tissue
under sterile conditions, and minced into approximately
1 mm3 pieces. After washing with modified Krebs’-
Ringer-Henseleit (KRH) solution ((in mmol/L) NaCl 115,
KCl 5, CaCl2 2, KH2PO4 1, MgSO4 1, glucose 15, N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES)
25 and 10 m g/mL phenol red, pH 7.4) containing 
100 U/mL penicilline G (Meiji Seika Co., Tokyo, Japan),
100 m g/mL streptomycin (Meiji) and 0.5 m g/mL ampho-
tericin B (Bristol-Myers Squibb Co., Tokyo, Japan) (PSA)
several times at 4°C, the minced muscle pieces were resus-
pended in 10 mL KRH solution containing PSA, not 2 but
0.2 mmol/L CaCl2, 6400 U collagenase (Sigma, St Louis,
MO, USA), 10 mg soybean trypsin inhibitor (Sigma) and
100 U elastase (Sigma), and then stirred gently for 90 min
at 37°C. The cell suspension was filtered through 100 m m
nylon meshes (Cell Strainer; Becton Dickinson Labware,
Franklin, NJ, USA), and centrifuged at 150 g for 10 min.
Cells were resuspended in Ham’s F-12 (GIBCO BRL,
Grand Island, NY, USA) containing 10% FBS (Sanko
Junyaku Co. Ltd, Tokyo, Japan) and PSA, seeded at a
density of 1 · 104/cm2 in 25 cm2 culture flasks (Becton
Dickinson Labware) and cultured in a humidified atmos-
phere at 37°C in 95% air/5% CO2 (v/v). The medium was
replaced every 2 days. After 5 to 7 days, when the cells
grew to confluence, they were subcultured by removal from
flasks with 0.25% trypsin (Difco Laboratories, Detroit, MI,
USA) and 0.01% ethylenediamine tetraacetic acid (EDTA)
(Dojindo, Kumamoto, Japan). These cell preparations
were identified as ASM cells by a characteristic ‘hill and
valley’ appearance and by immunocytochemical staining
with anti-a -smooth muscle actin monoclonal antibodies
(Sigma) detected by the alkaline phosphatase antialkaline
phosphatase method, as described previously.15 Cells at
passage numbers 5 to 10 were used for the following
experiments.
Culture of ASM cells with theophylline or
PDE inhibitors
Airway smooth muscle cells in Ham’s F-12 containing
10% FBS and PSA, were seeded at a density of 2 ·
104/mL in the wells of 24-well microplates (Becton
Dickinson Labware) in duplicate. After postincubation for
24 h, the culture medium was replaced with a fresh one
containing 2.5, 5 or 10% FBS without or supplemented
with theophylline (Wako Pure Chemical Industries, Ltd,
Osaka, Japan) (10–3 mol/L). The culture medium was
changed and the cell numbers were counted every 2 days.
The cells cultured in the presence of theophylline were
counted on the fourth day. Cell numbers were determined
by counting the released nuclei, as previously described.16
For each well, counting was performed three times.
To examine the effects of theophylline and PDE
inhibitors on the proliferation of ASM cells, after the 
cells were seeded and postincubated as mentioned
above, the culture medium was replaced with Ham’s
260 K MASU ET AL.
F-12 containing 5% FBS and PSA without or supplemented
with theophylline (10–5, 10–4, 3 · 10–4 and 10–3 mol/L),
cilostazol (provided by Ohtsuka Pharmaceutical Co. Ltd,
Tokyo, Japan;17 10–7, 10–6 and 10–5 mol/L), rolipram
(10–7, 10–6, 10–5 and 10–4 mol/L) or zaprinast (10–6, 
10–5 and 10–4 mol/L).18 Changing of the culture medium
was performed on the second day and counting on the
fourth day, as mentioned above.
Lactate dehydrogenase assay
Airway smooth muscle cells were cultured in Ham’s F-12
containing 5% FBS and PSA with or without theophylline
(10–4, 3 · 10–4 and 10–3 mol/L), rolipram (10–5 and 
10–4 mol/L) and cilostazol (10–7, 10–6 and 10–5 mol/L), as
described above. On the fourth day, the culture medium
was collected followed by the addition of 1 mL 5% Triton 
X-100 (Sigma) in Ham’s F-12 to each well. The content of
lactic dehydrogenase (LDH) in the culture medium and the
Triton X-100 solution was measured by an automatic ana-
lyzer (7350; Hitachi Kohki Co., Hitachinaka, Japan) as
extra- and intracellular LDH (LDHe and LDHi, respec-
tively). The LDH content in Ham’s F-12 containing 5% FBS
and PSA (LDHm) was also measured.
Lactic dehydrogenase release was calculated by the
following formula: 
Data analysis
Data are shown as mean ± SEM or mean ± SD and
were compared using Mann–Whitney U-test. Differences
were considered to be significant when P < 0.05.
RESULTS
The effect of theophylline on the proliferation
of ASM cells
As shown in Fig. 1, the number of cells was increased in
an FBS concentration-dependent manner. Because the
number reached the maximum on day 6 at all concen-
trations of FBS, the counting in the following experi-
ments was performed on day 4 when ASM cells grew 
subconfluently.
The effect of theophylline (10–3 mol/L) on ASM cell pro-
liferation was examined at 2.5, 5 or 10% of FBS. The
number of cells cultured in the presence of theophylline
was expressed as a percentage of that in the absence of
theophylline in each concentration of FBS. Theophylline
significantly inhibited the proliferation of ASM cells at all
concentrations of FBS (63.5% ± 10.6 (mean ± SD) at
2.5%; P < 0.01, 53.2% ± 12.4 at 5%; P < 0.01, and
60.9% ± 18.3 at 10% FBS; P < 0.01; Fig. 2a). However,
there was no significant difference in the inhibitory effect 
of theophylline between these concentrations of FBS.
The effect of various concentrations of theophylline
was also examined at the culture condition of 5% FBS.
The number of cells cultured in the presence of theo-
phylline was expressed as a percentage of that in the
absence of theophylline. The number of ASM cells was
significantly decreased by theophylline at concentrations
of 10–3 (59.7 ± 15.9%, P < 0.05) and 3 · 10–4 (59.7 ±
16.0%, P < 0.05) mol/L, but not at 10–4 (99.1 ± 23.5%)
and 10–5 (100.6 ± 10.4%) mol/L (Fig. 2b).
The effect of selective PDE inhibitors on the
proliferation of ASM cells
The number of cells cultured with a selective PDE III
inhibitor (cilostazol), a selective PDE IV inhibitor (roli-
pram), or a cGMP-specific PDE inhibitor (zaprinast), was
expressed as a percentage of that without the inhibitors.
Cilostazol significantly decreased the number in a 
dose-dependent manner (21.7% ± 7.0 at 10–5 mol/L; 
P < 0.01, 58.0% ± 29.0 at 10–6 mol/L; P < 0.01 and
77.8% ± 16.5 at 10–7 mol/L; P < 0.03; Fig. 3). Roli-
pram significantly inhibited the proliferation at concen-
trations of 10–4 (50.9% ± 7.4, P < 0.01) and 10–5 
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Fig. 1 Growth curve of airway smooth muscle cells in the
presence of various concentrations of fetal bovine serum (FBS).
Cells seeded at 2 · 104/well were cultured in the presence of
0% (h), 2.5% (d), 5% (n) and 10% (s) FBS and counted at




LDHi + (LDHe – LDHm)
· 100
(76.6% ± 10.7, P < 0.05) mol/L, but not at 10–6 (102.2%
± 23.5) and 10–7 (98.5 ± 17.8%) mol/L (Fig. 4). In con-
trast, zaprinast did not inhibit the number of ASM cells
(Fig. 5).
Release of LDH from ASM cells cultured
with agents
To examine whether or not the inhibitory effects of theo-
phylline, rolipram and cilostazol on ASM cell proliferation
were cytotoxic, LDH release was evaluated in each
culture condition. Lactic dehydrogenase release from
cells cultured with theophylline (10–3 mol/L, 2.4 ± 3.5%
(n = 3) and 3 · 10–4 mol/L, 10.4 ± 6.3% (n = 3)),
cilostazol (10–5 mol/L, 0.0 ± 0.0% (n = 3), 10–6 mol/L,
0.5 ± 0.5%(n = 3) and 10–7 mol/L, 2.1 ± 1.2% (n = 3))
and rolipram (10–4 mol/L, 0.0 ± 0.0% (n = 3) and 
10–5 mol/L, 0.0 ± 0.0% (n = 3)) was not significantly dif-
ferent from that with medium alone (6.4 ± 7.5% (n = 5)).
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Fig. 2 Effect of theophylline on
airway smooth muscle cell prolif-
eration. (a) Cells seeded at 2 ·
104/well were cultured with or
without theophylline (10–3 mol/ L)
in the presence of 2.5%, 5% and
10% fetal bovine serum (FBS),
and counted at day 4. (b) Cells
seeded at 2 · 104/well were
cultured with or without theophyl-
line (10–5, 10–4, 3 · 10–4 or 10–3
mol/L) at 5% FBS, and counted at
day 4. Data are expressed as
a percentage of counted cells
cultured without theophylline.
Each bar represents mean ± SD
of six experiments. *P < 0.05,
***P < 0.01.
Fig. 3 Effect of cilostazol on airway smooth muscle cell
proliferation. Cells seeded at 2 · 104/well were cultured with
cilostazol (10–7, 10–6 or 10–5 mol/L) at 5% fetal bovine serum,
and counted at day 4. Data are expressed as a percentage of
counted cells cultured without cilostazol. Each bar represents
mean ± SD of six experiments. **P < 0.03, ***P < 0.01.
Fig. 4 Effect of rolipram on airway smooth muscle cell prol-
iferation. Cells seeded at 2 · 104/well were cultured with
rolipram (10–7, 10–6, 10–5 or 10–4 mol/L) at 5% fetal bovine
serum, and counted at day 4. Data are expressed as a
percentage of counted cells cultured without rolipram. Each
bar represents mean ± SD of four experiments. *P < 0.05,
***P < 0.01.
DISCUSSION
In this study, we demonstrated for the first time that sel-
ective inhibitors of PDE isoenzyme type III (cilostazol) and
type IV (rolipram) inhibited the FBS-induced proliferation
of bovine ASM cells. The cAMP and cGMP content in
ASM cells was not measured, but it has been reported
that the inhibition of ASM cell proliferation, such as by
corticosteroids, was not associated with an elevation of
intracellular cAMP.19 However, it has been shown that
PDE III hydrolyzes mainly cAMP and PDE IV specifically
hydrolyzes cAMP,11 and that the inhibition of ASM cell
proliferation by agents that elevate the cAMP content,
including IBMX, (a non-selective PDE inhibitor), was cor-
related with cAMP levels,9 and, furthermore, that this
inhibitory effect was abolished by the addition of a sel-
ective inhibitor of cAMP-dependent protein kinase A
(PKA).10 In contrast, a cGMP-specific PDE inhibitor (zapri-
nast), showed no effect on the proliferation of ASM cells.
Therefore, it is very likely that the inhibitory effects of theo-
phylline, cilostazol and rolipram were mediated by the
increased content of cAMP. The mechanisms by which
cAMP inhibits the proliferation remains unclear. How-
ever, PDGF, which is a powerful mitogen of ASM cells in
serum,20 induces the proliferation of ASM cells through
the activation of the tyrosine kinase system and phos-
pholipase C.7 The abolition of the inhibitory effect by a
PKA inhibitor suggests the involvement of cAMP response
element binding protein, which binds to the cAMP
response element on the promoter region of target 
genes following phosphorylation by PKA, resulting in
subsequent gene transcription.21 Cyclic 3’,5’-adenosine
monophosphate might inhibit Ras-dependent Raf-1 acti-
vation resulting in MAP kinase activation that is required
for cell proliferation.22,23 Therefore, the inhibitory effect of
cAMP observed in this study might have been mediated
by the inhibition of tyrosine kinase pathway.
Consistent with the previous results using IBMX,9 theo-
phylline inhibited ASM cell proliferation. The inhibitory
activity of theophylline on ASM cell proliferation was
lower than that of IBMX, which can be explained by the
fact that the IC50 of theophylline on PDE activity is
higher by 10–60-fold.24 The lowest concentration exam-
ined at which the inhibitory effect of theophylline could
be achieved (3 · 10–4 mol/L) was still higher than the
therapeutic concentration in serum (0.5–1 · 10–4 mol/L),25
although the inhibitory effect was not cytotoxic to ASM
cells at the concentration used in this study, as indicated
by LDH release. A combination of submaximally effective
concentrations of sulbutamol and IBMX was reported
to have a greater inhibitory effect on thrombin-induced
mitogenesis in human ASM cells than that of either agent
alone.9 These results suggest that an inhibitory effect of
theophylline, even at therapeutic concentrations, could
be achieved by the combination with b -stimulants.
In addition to bronchospasm and airway inflam-
mation, airway remodeling, including hyperplasia/
hypertrophy of ASM cells leading to the amplification
of airway narrowing, has been targeted in the treatment
of bronchial asthma.26 However, the pathogenesis of
airway remodeling remains unclear, although there have
been a few studies investigating the contribution of
growth factors to the pathogenesis.15,27,28 Furthermore,
once it has begun, airway remodeling is difficult to
resolve, even by the administration of corticosteroids.29,30
Therapeutic strategies for airway remodeling have not
yet been reported, whereas effective treatments for
bronchoconstriction and airway inflammation, such as
by theophylline, b -agonists and corticosteroids, have
been developed. Our results indicating the inhibitory
effects of PDE inhibitors on ASM-cell proliferation
suggest the usefulness of these agents for the prevention
of airway remodeling. Further investigation that also
takes into account the bronchodilatory and anti-inflam-
matory effects31,32 of PDE inhibitors will be needed for
their development as anti-asthma drugs.
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Fig. 5 Effect of zaprinast on airway smooth muscle cell pro-
liferation. Cells seeded at 2 · 104/well were cultured with
zaprinast (10–6, 10–5 or 10–4 mol/L) at 5% fetal bovine serum
and counted at day 4. Data are expressed as a percentage 
of counted cells cultured without zaprinast. Each bar represents
mean ± SD of three experiments.
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